NLS Pharmaceutics Stock (NASDAQ:NLSP)
Previous Close
$1.96
52W Range
$1.71 - $20.80
50D Avg
$2.37
200D Avg
$5.17
Market Cap
$4.90M
Avg Vol (3M)
$1.20M
Beta
-0.52
Div Yield
-
NLSP Company Profile
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
NLSP Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HCWB | HCW Biologics Inc. |
| MOLN | Molecular Partners AG |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| RZLT | Rezolute, Inc. |
| TIL | Instil Bio, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| CTMX | CytomX Therapeutics, Inc. |
| LIXT | Lixte Biotechnology Holdings, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| ACHL | Achilles Therapeutics plc |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| KTTA | Pasithea Therapeutics Corp. |
| INDP | Indaptus Therapeutics, Inc. |
| PTIX | Protagenic Therapeutics, Inc. |